Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study.

The article presents a randomised controlled study that assessed the tolerability and safety of the oral platelet protease-activated receptor-1 antagonist SCH530348. The study was conducted in response to the need for an antithrombotic drug that safely reduces cardiovascular events in patients undergoing percutaneous coronary intervention (PCI). Patients undergoing non-urgent PCI or coronary anigography with planned PCI were randomly assigned to SCH 530348 or matching placebo. The incidence of clinically significant major or minor bleeding according to the thrombolysis in myocardial infarction scale was the primary endpoint. Researchers found that SCH 530348 was well tolerated and did not cause increased thrombolysis in myocardial infarction (TIMI) bleeding.